We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial strategy and operations for life science companies – Stoke Therapeutics...
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
– As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 – Stoke Therapeutics, Inc. (Nasdaq:...
– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.33 | 2.82292557742 | 11.69 | 12.73 | 10.97 | 844620 | 11.7328122 | CS |
| 4 | -0.16 | -1.31362889984 | 12.18 | 13.82 | 10.9 | 958178 | 12.06551442 | CS |
| 12 | 7.65 | 175.057208238 | 4.37 | 16.3999 | 4.09 | 1349605 | 11.44165583 | CS |
| 26 | 7.84 | 187.559808612 | 4.18 | 16.3999 | 3.77 | 738208 | 10.48030971 | CS |
| 52 | 2.11 | 21.2916246216 | 9.91 | 16.3999 | 3.35 | 532000 | 9.58545928 | CS |
| 156 | -20.39 | -62.9126812712 | 32.41 | 41.6 | 3.35 | 345515 | 13.15187087 | CS |
| 260 | -15.19 | -55.8250643146 | 27.21 | 71.58 | 3.35 | 275252 | 17.64826788 | CS |
Zardiw
1 month ago
TimeFades
1 month ago
TimeFades
1 month ago
TimeFades
1 month ago
Invest-in-America
1 month ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
